BrainStorm Cell Therapeutics Presents Breakthrough Phase I/II ALS Clinical Data at the American Academy of Neurology Annual

BrainStorm Cell Therapeutics Presents Breakthrough Phase I/II ALS Clinical Data 
at the American Academy of Neurology Annual Meeting 
American Academy of Neurology's Annual Meeting Being Held March 16-23
at the San Diego Convention Center; BrainStorm Presentation: Emerging
Science Session on Wednesday, March 20, 2013 
NEW YORK, NY and PETACH TIKVAH, ISRAEL -- (Marketwire) -- 03/13/13 --
 BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of
adult stem cell technologies for neurodegenerative diseases, will be
presenting the initial results of its Phase I/II ALS trial at the
65th Annual Meeting of the American Academy of Neurology (AAN) in San
Diego, California, from March 16-23. BrainStorm's groundbreaking
clinical trial data were selected for one of only twelve oral
presentations in the Emerging Science Session on Wednesday, March
20th.  
The presentation, to be made by Principal Investigator Professor
Dimitrios Karussis of the Hadassah Medical Center in Jerusalem, will
be the first to make public the outstanding Phase I/II clinical trial
safety data and promising initial indications of clinical efficacy
observed after treatment with NurOwn(TM), BrainStorm's stem cell
therapy candidate for ALS.  
"We are honored to present these important clinical data at the most
prestigious world neurology meeting," commented Professor Karussis.
"We are confident that the results observed so far will be indicative
of the potential therapeutic benefit of NurOwn cells for treatment of
ALS," he added.  
The American Academy of Neurology Annual Meeting is one of the
world's most important annual events for neurologists and
neuroscience professionals and the largest such international meeting
of its kind with more than 12,000 attendees at last year's meeting.
For more information about the AAN annual meeting and for a complete
list of abstracts, please refer to the conference Web site at
http://www.aan.com/go/am13. 
The following is the key NurOwn(TM)-related abstract being presented
at the AAN meeting: 


 
                                                                            
                      Session                     First                     
Abstract #   Type      Title         Title        Author     Date     Time  
               
                                                             
                               Interim Analysis                             
                                of 12 Patients                              
                                 w/Amyotrophic                              
                                    Lateral                                 
                                Sclerosis (ALS)                             
            Oral +    Emerging      Treated     Dimitrios                   
    008     Poster    Science    w/Autologous   Karussis, Wednesday 5:45pm- 
          Presentati  Session   Differentiated   MD, PhD   March 20  7:00pm 
              on               Mesenchymal Stem                             
                                    Cells:                                  
                               Preliminary Data                             
                                of a Phase I/II                             
                                Clinical Trial                              

 
About NurOwn(TM)
 NurOwn is an autologous, adult stem cell therapy
technology that differentiates bone marrow-derived mesenchymal stem
cells (MSC) into specialized, neuron-supporting cells. These
neuron-supporting cells (known as "MSC-NTF" cells) secrete
neurotrophic, or nerve-growth, factors for PROTECTION of existing
motor neurons, PROMOTION of motor neuron growth, and RE-ESTABLISHMENT
of nerve-muscle interaction. The ability to differentiate mesenchymal
stem cells into MSC-NTF cells, and confirmation of their activity and
potency before transplantation, makes NurOwn a first-of-its-kind
approach for treating neurodegenerative diseases. More information
about NurOwn(TM) can be found at
http://brainstorm-cell.com/index.php/science-a-technology/-nurown. 
About BrainStorm Cell Therapeutics, Inc. 
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged
in the development of first-of-its-kind adult stem cell therapies
derived from autologous bone marrow cells for the treatment of
neurodegenerative diseases. The Company holds the rights to develop
and commercialize its NurOwn technology through an exclusive,
worldwide licensing agreement with Ramot, the technology transfer
company of Tel Aviv University. For more information, visit the
company's website at www.brainstorm-cell.com. 
Safe Harbor Statement - Statements in this announcement other than
historical data and information constitute "forward-looking
statements" and involve risks and uncertainties that could cause
BrainStorm Cell Therapeutics Inc.'s actual results to differ
materially from those stated or implied by such forward-looking
statements. Terms and phrases such as "may", "should", "would",
"could", "will", "expect", "likely", "believe", "plan", "estimate",
"predict", "potential", and similar terms and phrases are intended to
identify these forward-looking statements. The potential risks and
uncertainties include, without limitation, risks associated with
BrainStorm's limited operating history, history of losses; minimal
working capital, dependence on its license to Ramot's technology;
ability to adequately protect the technology; dependence on key
executives and on its scientific consultants; ability to obtain
required regulatory approvals; and other factors detailed in
BrainStorm's annual report on Form 10-K and quarterly reports on Form
10-Q available at http://www.sec.gov. These factors should be
considered carefully, and readers should not place undue reliance on
BrainStorm's forward-looking statements. The forward-looking
statements contained in this press release are based on the beliefs,
expectations and opinions of management as of the date of this press
release. We do not assume any obligation to update forward-looking
statements to reflect actual results or assumptions if circumstances
or management's beliefs, expectations or opinions should change,
unless otherwise required by law. Although we believe that the
expectations reflected in the forward-looking statements are
reasonable, we cannot guarantee future results, levels of activity,
performance or achievements. 
CONTACTS
BrainStorm Cell Therapeutics Inc.
Mr. Alon Natanson
CEO
Phone: +972-3-9236384
info@brainstorm-cell.com
www.brainstorm-cell.com 
LifeSci Advisors, LLC
Michael Rice
Founding Partner
646-597-6979
mrice@lifesciadvisors.com
www.LifeSciAdvisors.com 
 
 
Press spacebar to pause and continue. Press esc to stop.